Researchers at MIT have developed and publicly released an AI-driven model that forecasts the long-term stability of Chinese Hamster Ovary (CHO) cell lines used extensively in biotherapeutic production. The model analyzes epigenetic data to predict productivity retention over 72 cell passages, aligning with FDA stability definitions. This tool promises to enhance manufacturing consistency, reduce development timelines, and improve quality control in biologics production processes.